Literature DB >> 32378319

Pyoderma gangrenosum: From historical perspectives to emerging investigations.

Misty M Hobbs1, Alex G Ortega-Loayza2.   

Abstract

Pyoderma gangrenosum (PG) is a rare disease of unknown aetiology, first described over a century ago. Initially thought to have an infectious cause, and now primarily considered an autoinflammatory condition, PG continues to be poorly understood, commonly misdiagnosed, and difficult to treat. In this review, we discuss the journey of our understanding of PG to date, including first descriptions, challenges with diagnosis, presumed pathogenesis, and treatments used. We highlight major historical landmarks and their importance, explain the rationale behind current investigations, note outstanding gaps in knowledge, and explore the future directions of PG research. We summarise what we have known, what we are working on knowing, and what we have yet to explore about PG, illustrating overall trends to invigorate future research.
© 2020 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  emerging; historical; pyoderma gangrenosum; review; trends

Year:  2020        PMID: 32378319      PMCID: PMC7949187          DOI: 10.1111/iwj.13389

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  92 in total

1.  Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease.

Authors:  L Arturo Batres; Petar Mamula; Robert N Baldassano
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-05       Impact factor: 2.839

2.  Adalimumab treatment for pyoderma gangrenosum.

Authors:  Michael P Heffernan; Milan J Anadkat; David I Smith
Journal:  Arch Dermatol       Date:  2007-03

3.  Evaluating the Efficacy of Topical Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Case Series.

Authors:  David G Li; Ryan S Din; William G Tsiaras; Arash Mostaghimi
Journal:  J Cutan Med Surg       Date:  2018 Nov/Dec       Impact factor: 2.092

4.  Intravenous cyclophosphamide pulses in pyoderma gangrenosum: an open trial.

Authors:  C Reynoso-von Drateln; A V Perla-Navarro; J I Gamez-Nava; L Gonzalez-Lopez; F Galvan-Villegas; C Ramos-Remus
Journal:  J Rheumatol       Date:  1997-04       Impact factor: 4.666

Review 5.  Present status of immunological mechanisms in ulcerative colitis.

Authors:  S C Kraft; J B Kirsner
Journal:  Gastroenterology       Date:  1966-11       Impact factor: 22.682

6.  Efficacy of human intravenous immune globulin in pyoderma gangrenosum.

Authors:  A K Gupta; N H Shear; D N Sauder
Journal:  J Am Acad Dermatol       Date:  1995-01       Impact factor: 11.527

7.  Severe steroid responsive pneumonitis associated with pyoderma gangrenosum and ulcerative colitis.

Authors:  A J McCulloch; A McEvoy; J D Jackson; E H Jarvis
Journal:  Thorax       Date:  1985-04       Impact factor: 9.139

8.  Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.

Authors:  Emmanuella Guenova; Anna Teske; Birgit Fehrenbacher; Sebastian Hoerber; Annette Adamczyk; Martin Schaller; Wolfram Hoetzenecker; Tilo Biedermann
Journal:  Arch Dermatol       Date:  2011-06-16

9.  Differential in situ expression of IL-17 in skin diseases.

Authors:  Mattias Fischer-Stabauer; Alexander Boehner; Stefanie Eyerich; Teresa Carbone; Claudia Traidl-Hoffmann; Carsten B Schmidt-Weber; Andrea Cavani; Johannes Ring; Ruediger Hein; Kilian Eyerich
Journal:  Eur J Dermatol       Date:  2012 Nov-Dec       Impact factor: 3.328

Review 10.  Pyoderma gangrenosum.

Authors:  J G Hickman
Journal:  Clin Dermatol       Date:  1983 Jul-Sep       Impact factor: 3.541

View more
  3 in total

1.  Pyoderma gangrenosum: From historical perspectives to emerging investigations.

Authors:  Misty M Hobbs; Alex G Ortega-Loayza
Journal:  Int Wound J       Date:  2020-05-06       Impact factor: 3.315

2.  A Case of Recurrent Idiopathic Pyoderma Gangrenosum.

Authors:  Filipa David; Rafaela Lopes Freitas; Rute Brás-Cruz; Joana Rocha; Cristina Rosário
Journal:  Cureus       Date:  2022-05-18

3.  Adjunctive Hyperbaric Oxygen Therapy in Refractory Crohn's Disease: An Observational Study.

Authors:  Marley R Feitosa; Rogério S Parra; Vanessa F Machado; Gustavo N Vilar; Jussara C Aquino; José J R Rocha; Paulo G Kotze; Omar Féres
Journal:  Gastroenterol Res Pract       Date:  2021-04-26       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.